eXmoor Pharma has formed a strategic collaboration with University College London’s Translational Research Office (TRO) to support earlier and more efficient translation of cell and gene therapy projects from academic research into first-in-human studies.

The partnership connects UCL researchers with eXmoor’s consultancy, development and GMP manufacturing teams at an earlier stage, aiming to reduce the technical, regulatory and cost barriers that often slow progress towards clinical trials. The agreement covers areas including CMC strategy, process and analytical development, and GMP manufacturing for early clinical studies, alongside guidance on grant applications and translational planning.

Both organisations said the collaboration reflects a shared focus on improving how academic CGT innovations move into clinical development. UCL’s TRO will provide translational research input, while eXmoor will offer cross-modality expertise spanning viral vectors, autologous and allogeneic cell therapies and RNA technologies.

Academic teams will be able to access structured consultancy clinics, joint events and routes into eXmoor’s laboratory and GMP capacity. The intention is to give researchers clearer, earlier visibility of practical requirements for scale-up, regulatory compliance and commercial feasibility.

Angela Osborne, founder and executive chair of eXmoor Pharma, said: “The strength of the UK’s academic science has always been clear but getting groundbreaking therapies from the lab to patients requires a collaborative approach. This partnership with UCL TRO reflects our shared belief that supporting translational research with practical, GMP-ready solutions is the key to unlocking meaningful outcomes for patients. We’re pleased to play a role in helping academic innovation become clinical reality.”

Pamela Tranter, head of the Translational Research Group at UCL Translational Research Office, added: “UCL is committed to driving innovation that transforms lives, with a world-leading pipeline of Advanced Therapy Medicinal Products (ATMPs). Through this strategic partnership, we look forward to connecting UCL researchers with eXmoor’s expertise, supporting closer collaboration with industry and the development of practical, scalable plans that could help realise therapeutic potential.”